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Myocardial Infarction: The Role of Loading History
Theresa R. Cassino, Ph.D.,1–3,* Lauren Drowley, Ph.D.,2,4,* Masaho Okada, M.D., Ph.D.,1,2
Sarah A. Beckman, B.S.,2,4 Bradley Keller, M.D.,3,5,6 Kimimasa Tobita, M.D.,5,6
Philip R. LeDuc, Ph.D.,3 and Johnny Huard, Ph.D.1,2,4,5
Stem cell therapy for tissue repair is a rapidly evolving field and the factors that dictate the physiological
responsiveness of stem cells remain under intense investigation. In this study we hypothesized that the me-
chanical loading history of muscle-derived stem cells (MDSCs) would significantly impact MDSC survival, host
tissue angiogenesis, and myocardial function after MDSC transplantation into acutely infarcted myocardium.
Mice with acute myocardial infarction by permanent left coronary artery ligation were injected with either
nonstimulated (NS) or mechanically stimulated (MS) MDSCs. Mechanical stimulation consisted of stretching the
cells with equibiaxial stretch with a magnitude of 10% and frequency of 0.5Hz. MS cell-transplanted hearts
showed improved cardiac contractility, increased numbers of host CD31 + cells, and decreased fibrosis, in the
peri-infarct region, compared to the hearts treated with NS MDSCs. MS MDSCs displayed higher vascular
endothelial growth factor expression than NS cells in vitro. These findings highlight an important role for cyclic
mechanical loading preconditioning of donor MDSCs in optimizing MDSC transplantation for myocardial
repair.
Introduction
Stem cell transplantation is emerging as a promisingtherapy for the regeneration of numerous tissues, in-
cluding heart disease, muscular dystrophy, diabetes, hemo-
philia, multiple sclerosis, and Parkinson’s disease.1–3 Cardiac
disease, particularly myocardial infarction, is a leading cause
of mortality and morbidity worldwide, and the current
standard practice cannot reverse the progressive deteriora-
tion in cardiac function that typically occurs after injury or
disease.4 Cell therapy for cardiac repair is a rapidly ex-
panding area of research, with a wide variety of cell types
under investigation.2,5–7 Progenitor and stem cells can be
derived from most vascularized tissues in the body, and
skeletal muscle-derived cells have shown particular promise
for muscle repair due to their autologous origin, in vitro
scalability, and high resistance to stress. We have previously
isolated a population of early myogenic progenitors called
muscle-derived stem cells (MDSCs) based on their selective
adherence to collagen-coated flasks.8,9 MDSCs are multi-
potent; have been shown to differentiate along skeletal, car-
diac and smooth muscle, bone, cartilage, tendon, nerve,
endothelial, and hematopoietic lineages; and display a high
regenerative potential after transplantation.9–13 MDSCs have
been shown to regenerate cardiac and skeletal muscle in a
more effective manner than myoblasts.13,14
While stem cell transplantation has produced promising
initial results, many of the stem cell-mediated improvements
in cardiac function are only transient. One main barrier to
successful cardiac cell therapy is low cell survival due to
initial cell death postimplantation, subsequent biological cell
death,15 and immune-mediated cell destruction.16,17 The
post-transplantation in vivo cellular response is influenced by
many factors in the cellular microenvironment, including the
extracellular matrix, growth factors, cytokines, and mechan-
ical loading. For example, improved cardiac repair after
myocardial infarction has been shown to occur when vascular
endothelial growth factor (VEGF) secretion is increased.18 The
activation of signaling pathways by pharmacologically pre-
conditioning skeletal myoblasts promotes their survival by
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inducing the release of paracrine factors that stimulate an-
giogenesis in the infarcted heart.19
Mechanical and structural cues have been shown to play a
critical role in tissue physiology, including cell growth, mi-
gration, gene expression, and cell signaling,20,21 and this may
play a role in cell transplantation since most cells and tissues
experience biomechanical forces within the body.20 Indeed, it
has been recently shown that culturing muscle-derived cells
on soft hydrogel substrates that mimic the elasticity of
muscle, self-renew in vitro and regenerate skeletal muscle in
a more effective manner than muscle-derived cells grown on
rigid plastic dishes.22 However, no consensus has been
reached as to the tissue-specific roles that these mechanical
forces play in healing and regeneration. Evidence is emerg-
ing that mechanical preconditioning can impact post-
implanted stem cell survival, proliferation, and participation
in tissue regeneration.23–26 For example, skeletal muscle is
known to respond to mechanical stimulation by regulating
the production of structural proteins, including actin and
myosin.27 Mechanical stretch also plays an important role in
the proliferation of mesenchymal stem cells,28 and a recent
report indicates that the application of cyclic stretch can in-
duce the proliferation of satellite cells and inhibit their dif-
ferentiation into myotubes.29 The effect of mechanical
preconditioning on biochemical and structural responses
suggests that the mechanical loading history experienced by
cells in vitro or in vivo may affect cellular behavior to a
greater extent than previously thought.
Our current study investigates the impact of MDSC
loading history on the regenerative capacity of MDSCs for
cardiac muscle. In a mouse model of acute myocardial in-
farction, mechanically stimulated (MS) MDSCs attenuated
the decline of cardiac function to a greater extent than non-
stimulated (NS) MDSCs or phosphate-buffered saline (PBS)
alone. We investigated the effects of mechanically pre-
conditioning cells in vitro to ascertain changes in cell be-
havior. We analyzed paracrine factor secretion, resistance to
oxidative stress, antioxidant capacity, proliferation, and dif-
ferentiation toward skeletal muscle. Through these studies,
we confirm that mechanical preconditioning can influence
the paracrine effect of MDSCs (angiogenic factor secretion),
reduce scar tissue, and consequently improve cardiac re-
covery after stem cell transplantation.
Materials and Methods
MDSC isolation
MDSCs were isolated from the skeletal muscle of 3-week-
old normal C57BL/10J mice ( Jackson Laboratories) using the
modified preplate technique as previously described.8
MDSCs were cultured in a proliferation medium (PM) con-
taining Dulbecco’s modified Eagle’s medium (DMEM; In-
vitrogen), 10% fetal bovine serum (Invitrogen), 10% horse
serum (Invitrogen), 1% penicillin/streptomycin (Invitrogen),
and 0.5% chick embryo extract (Accurate Chemical).
Mechanical stimulation
MDSCs were cultured on bioflex plates, which are flexible
bottomed six-well culture plates coated with collagen I
(100,000 cells/well; Flexcell Intl. Corp.). After 12 h of culture,
an FX-4000T strain unit was used to subject the cells to 10%
equibiaxial strain with a 0.5-Hz sine wave for the designated
time period as previously described.18 Control MDSCs were
cultured on bioflex plates as described without strain. The
mechanical stimulation conditions were chosen based on
previous studies that indicated increased VEGF secretion
under these conditions in vitro.18,30,31
In vitro studies
In vitro MDSC proliferation activity. After exposure to
mechanical strain, cells were replated on 24-well collagen-
coated plates and then placed onto a previously described32
live cell imaging system (Automated Cell, Inc.), and fluo-
rescent and brightfield images were taken every 10min in
three locations per well. These images were analyzed using
ImageViewer software (ACI) and the number of cells was
counted at 12-h intervals to track proliferation rates.
Cell survival under oxidative stress
Preconditioned cells were plated in PM at a density of
1000 cells/well in a 24-well collagen-coated plate and then
assessed for cell survival as previously described.32 Briefly,
24 h after plating the medium was switched to PM or PM
containing 400mM hydrogen peroxide and propidium iodide
(PI, 1mL/500mL medium; Sigma). The plates were then
placed onto a live cell imaging system (Automated Cell, Inc.)
and fluorescent and brightfield images were taken every
10min in three locations per well. These images were ana-
lyzed using ImageViewer software (Automated Cell, Inc.).
Cell survival (n = 21) was determined by counting the num-
ber of PI-positive cells in the fluorescent images and the
number of cells present in the brightfield images at the 12-h
time point.
In vitro myogenic differentiation
Differentiation toward skeletal muscle was assessed as
previously described.33 Cells were plated on 24-well plates
after mechanical stimulation, and 24 h later the medium was
changed to DMEM containing 2% serum, which induces
myotube differentiation. At 10 days, the plates were stained
with a mouse primary antibody for anti-fast skeletal myosin
heavy chain (fsMHC) (1:500; Sigma), Alexafluor 488 donkey
anti-mouse secondary antibody (1:400; Molecular Probes),
and 4¢,6-diamidino-2-phenylindole (DAPI, for nuclei). We
then determined the fusion index of the cells, which is an
indicator of myogenic differentiation,34 by calculating the
percentage of nuclei in the fused myotubes (n= 15) in three
images per well in three different wells per treatment group
(fusion index =number of nuclei in fused myotubes/total
number of nuclei).
In vitro VEGF expression
Cells were MS as described above in DMEM with 1%
penicillin/streptomyocin for 24 h (MS). Cells were stimu-
lated for 24 h, allowed to rest for 24 h (MS rest), and then
stimulated again (MS rest MS). The conditioned medium
was collected for each sample and flash frozen. VEGF se-
cretion was quantified by an enzyme-linked immunosorbant
assay (ELISA) for mouse VEGF according to the manufac-
turer’s instructions (R&D Systems) and normalized to cell
number.
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Animal studies
The use of animals and the surgical procedures performed
in this study were approved by the Institutional Animal Care
and Use Committee of the Children’s Hospital of Pittsburgh
of University of Pittsburgh Medical Center (protocol 14/06).
Cell transplantation into infarcted myocardium
Fifty adult male immunodeficient C57BL/6J-Prkdcscid
mice (12 weeks old) were obtained from Jackson Labora-
tories and bred for the current study at the institution’s an-
imal facility. An acute infarction model was used to assess
the efficacy of mechanical stimulation on cardiac transplan-
tation of the MDSCs. The mice underwent permanent left
anterior descending coronary artery ligation using a 7-0
prolene suture to create a myocardial infarction as previ-
ously described.13,35,36 Infarcted mice were randomly allo-
cated between the treatment groups (PBS, nonstretch MDSCs
[NS], or 24-h stretch MDSCs [MS]). Five minutes after per-
manent ligation of the artery, 3 · 105 cells in 30mL of PBS
(three injections of 10 mL each) were injected into the anterior
and lateral aspects of the left ventricular free wall bordering
the infarct zone, and into the center of the infarct. Male se-
vere combine immunodeficient (SCID) mice 13–16 weeks of
age were used following a protocol previously described.13,18
Echocardiography
Two, 6, and 12 weeks after cell injection, echocardiogra-
phy was performed by a blinded investigator on the left
ventricular short axis view at the mid-papillary muscle level
as described previously18 to assess cardiac function. Left
ventricular end-diastolic area and end-systolic area were
measured from short axis images of the left ventricle, and
end-diastolic dimensions and end-systolic dimensions were
measured from M-mode tracing. After echocardiography
the mice were euthanized and the hearts flash-frozen in 2-
methylbutane and cryosectioned.13,18
Identification of CD31 + cells
within the injected myocardium
The number of CD31+ cells in the engraftment area was
determined by double-staining tissue sections with rat anti-
CD31 primary antibody (1:300; Sigma) and Alexafluor 555
donkey anti-rat secondary antibody (1:300; Molecular Probes),
andmouse anti-fsMHCantibody (1:400; Sigma) andAlexafluor
488 goat anti-mouse (1:200; Sigma). CD31+ vessel formation
within the cell-injected areas was determined by counting the
number of CD31(+ ) cells associated with fsMHC(+ ) cells
within the infarct area. fsMHC-positive cells represent donor
MDSCs in the cardiac tissue.36 Blood vessel formation in the
peri-infarct area was determined by staining with rat anti-
CD31 primary antibody (1:300; Sigma) and Alexafluor 555
donkey anti-rat secondary antibody (1:300; Molecular Probes).
The number of CD31+ cells in three high-powered images in
the peri-infarct area was quantified in each heart.
Identification and quantification of transplanted
MDSCs in infarcted myocardium
Cryosections were fixed in 4% paraformaldehyde and
then stained to determine donor cell engraftment. Heart
sections were stained with mouse anti-fsMHC antibody
(1:400; Sigma) and Alexafluor 555 donkey anti-mouse sec-
ondary antibody (1:300; Molecular Probes) to examine en-
graftment of the different cell populations. The number of
engrafted cells was determined by assessing the area of
fsMHC( + ) cells normalized to the area of the entire muscle
section.34
Staining for cardiac-specific markers in vivo
Sections from the infarcted samples were stained with
mouse anti-fsMHC (1:400; Sigma) and Alexafluor 488 don-
key anti-mouse secondary antibody (1:300; Molecular
Probes), and goat anti-cardiac troponin I (cTnI, 1:25,000;
Scripps) with rabbit anti-goat Alexafluor 555 (1:200; Mole-
cular Probes). The number of double-positive cells was
counted in three high powered fields per heart.
Scar tissue area fraction
Infarcted heart sections were fixed with 1% gluter-
aldehyde for 2min and stained with the Masson Modified
IMEB Trichrome Stain Kit (IMEB). Trichrome staining was
performed according to the manufacturer’s guidelines as
previously described.13,18 The sections were assessed for the
percentage area of collagen-positive area normalized to total
muscle area within the sections using ImageJ software (NIH).
Microscopy
Fluorescence and brightfield microscopy were performed
using either a Nikon Eclipse E800 microscope (Nikon Corp.)
or a Leica inverted microscope (Leica Microsystems) with a
Retiga EXi digital camera (Q Imaging) and Northern Eclipse
software (version 6.0; Empix Imaging, Inc.). Image analysis
was performed using Northern Eclipse software.
Statistical analysis
Data are expressed as mean– standard error of the mean.
Student’s t-test was used to compare the in vitro prolifera-
tion and cell survival and CD31 expression in the infarction
area (a= 0.05; Excel). Echocardiography data were analyzed
by using two-way-repeated measure analysis of variance
(ANOVA). All other statistical analysis was determined by
one-way ANOVA. In the event of a significant ANOVA,
the Tukey test was used for post hoc analysis (SPSS v. 16.0;
SPSS, Inc.).
Results
In vitro proliferation of MDSCs is increased
with mechanical stretch, but differentiation
and resistance to oxidative stress is not affected
The proliferation rate of MDSCs after mechanical stimu-
lation was initially similar to the proliferation rate of NS
cells, but by 48 h, the MS-MDSCs displayed a higher prolif-
eration rate ( p= 0.04, Fig. 1a). The post-transplantation mi-
croenvironment is known to be hostile to transplanted cells
with oxidative stress playing a significant role in that pro-
cess. We therefore evaluated the effect of MS on the MDSCs
response to oxidative stress. Mechanically preconditioned
cells (n = 21) showed similar levels of survival under oxida-
tive stress versus NS controls (n = 21, 12 h: p = 0.48, 24 h:
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p = 0.68, 24 h: p= 0.62, 36 h: p = 0.72, 48 h: p= 0.71, 60 h:
p = 0.52, Fig. 1b). Myotube formation, an index of myogenic
differentiation capacity, was also unaffected by mechanical
stimulation (n = 15 per treatment, p= 0.89 NS to MS, p= 0.94
NS to MS rest, p= 0.99 MS to MS rest, Fig. 1c).
Mechanical stimulation increased the in vitro
expression of VEGF by the MDSCs
Previous results have shown that MDSCs exposed to MS
resulted in increased VEGF secretion.18 We consequently ex-
amined the effect of MS on the time course of VEGF secretion
and confirmed that in vitro mechanical stimulation increased
VEGF secretion (MS [n= 6]: 937– 148pg/mL; p= 0.01 MS to
NS; NS [n= 6]: 248– 80pg/mL; Fig. 2); however, if mechanical
stimulation was followed by 24h of static culture (MS rest),
secreted VEGF levels returned to the level of the NS cells
(n= 6, 254– 30pg/mL, p= 0.91 NS to MS rest). We then re-
stimulated the cells for 24 h and found that cells re-exposed to
MS (MS rest MS) showed an increase in VEGF secretion (n= 6,
426– 36pg/mL, p= 0.99 NS to MS rest MS), but this increase
was much lower than the initial MS levels. These results
provide evidence that the effect of mechanical stimulation on
MDSCs is time dependent in vitro, as VEGF secretion is shown
to be dependent on mechanical loading history.
Mechanical preconditioning preserved cardiac
function after myocardial infarction
To quantify the efficacy of mechanical preconditioning of
donor MDSCs on the regenerative capacity of host myocar-
dium, we compared MS MDSCs with NS MDSCs for their
ability to aid in the functional recovery of myocardial infarct
injured hearts. The most critical endpoint in cell transplan-
tation for cardiac repair is maintenance or improvement of
cardiac contractility and output. Therefore, cardiac function
was assessed at 2, 6, and 12 weeks after cell transplantation
to determine the effect of preconditioning on the attenuation
of postinfarction cardiac functional deterioration. Hearts
treated with MS-MDSCs had significantly higher systolic
function as indicated by fractional shortening versus NS
MDSCs or PBS injected control hearts (Fig. 3a and Table 1).
Fractional area change, another index of systolic cardiac
function, further confirmed that MS-MDSCs were better able
to preserve systolic function after myocardial infarction
versus NS MDSCs or PBS-injected control hearts (Fig. 3b and
Table 1).
Mechanical stimulation significantly increased
the number of CD31 + cells after myocardial infarction
We explored the impact of MS-MDSCs on the number of
CD31 + cells within the injected hearts, as blood vessel for-
mation has been previously shown to be critical for cardiac
repair.18 A significant difference in the numbers of CD31+
cells in the peri-infarct region at 12 weeks (Fig. 4a) was ob-
served between MS MDSCs (21 – 1 CD31+ cells/mm2, n = 5,
p = 0.01 to NS, p = 0.0004 to PBS), NS MDSCs (14– 1 CD31+
cells/mm2, n = 5, p = 0.03 to PBS), and PBS (9 – 1 CD31+
cells/mm2, n = 4) (12 weeks). A similar trend was found
when examining the number of CD31+ cells in the engraft-
ment region (fsMHC + areas) ( p= 0.11, Fig. 4b). The data
shown are the mean– standard error of the mean.
FIG. 1. In vitromechanical stimulation did not affect differentiation or survival, but increased proliferation. (a)Mechanically
stimulated (MS) cells (open square, 24 h stimulation) had significantly higher proliferation than nonstimulated (NS) (closed
diamond, 0 h stimulation) at 48 h post-treatment (*p < 0.05). (b). Cell survival was similar between the groups (MS cells [open
square, 24 h stimulation], and NS [closed diamond, 0 h stimulation]) exposed to oxidative stress. (c) There was no difference
in the differentiation capacity after 10 days between the groups (NS, MS, MS rest [24 h of stimulation then 24 h of rest]).
FIG. 2. In vitro mechanical stimulation increases vascular
endothelial growth factor (VEGF) expression. VEGF was
increased after 24 h of mechanical stimulation (MS), *p < 0.05.
The VEGF overexpression was abolished when the cells were
removed from mechanical stimulation for 24 h (MS rest) and
slightly increased after a second MS period (MS rest MS).
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Mechanical stimulation does not affect cell survival
and cardiac differentiation in vivo
Despite a positive effect imparted by the MS-MDSCs on
cardiac functional recovery, MDSC cell survival in vivo was
similar between the MS and NS groups (6 weeks: n= 3 per
group, p= 0.24; 12 weeks: n= 5 per group, p= 0.47; data not
shown). Previously, we found only low levels of in vivo
MDSC differentiation toward a cardiac phenotype13,14 that
was confirmed in the current study, with less than 1 out of
100 injected cells coexpressing cTnI and fsMHC at 6 or 12
weeks after injection (data not shown). There were no dif-
ferences observed between the MS and NS cells (6 weeks:
n= 3 per treatment, p = 0.72; 12 weeks: n= 5 per treatment,
p= 0.95; data not shown). These results imply that the in-
crease in cardiac function seen with MS-MDSCs is not related
to MDSC differentiation along the cardiac lineage nor is it
related to differences in cell survival.
Mechanical stimulation of MDSCs significantly reduced
scar tissue area compared with the PBS control
The scar tissue area fraction, defined as the ratio of colla-
gen-rich fibrous tissue to total cardiac muscle area, is known
to affect myocardial function after infarction, with lower
levels correlating with a greater degree of cardiac contrac-
tility.37 A similar degree of scar tissue formation was ob-
served in the MS-MDSC group at both 6 and 12 weeks (6
weeks: 58%– 6%, n= 3, p= 0.98 to NS; 12 weeks: 45%– 5%,
n= 6, p= 0.30 to NS) versus the NS cells (6 week: 66%– 2%,
n= 3, p= 0.06 to PBS; 12 weeks: 57%– 7%, n = 5, p= 0.07 to
PBS; Fig. 5a); however, the MS-MDSC-injection group had
significantly lower levels of scar tissue than the PBS controls
at both time points tested (6 weeks: p = 0.04 to PBS; 12 weeks:
p= 0.003 to PBS) (6-week PBS: 80% – 5%; 12-week PBS:
76%– 2%).
Discussion
Examining loading history through mechanical pre-
conditioning of MDSCs increases the understanding of stem
cell biology along with providing a potential method to
improve cell transplantation for the treatment of disease and
injury. The experiments reported here show that the ex-
pression of VEGF plays a potential role in the beneficial effect
of mechanical stimulation of MDSCs for cellular cardio-
myoplasty. In addition, the increase in CD31+ cells and re-
duction in scar tissue formation at the injection sites, likely
play a role in the improved cardiac function after injury seen
in the MS-MDSC group compared to the PBS control group.
Cellular behavior in vivo is influenced by a dynamic mi-
croenvironment that includes a diverse extracellular matrix,
growth factors, cytokines and other soluble factors, and dy-
namic mechanical forces. The behavior of stem cells, in par-
ticular, may be significantly regulated by the cellular
microenvironment and local cues that maintain quiescence or
can trigger tissue repair and regeneration. Although cells and
FIG. 3. Cardiac function was improved by mechanically
preconditioning the muscle-derived stem cells (MDSCs). (a)
Hearts treated with MS-MDSCs had improved fractional
shortening over the NS MDSCs and phosphate-buffered sa-
line (PBS) groups. *p< 0.05 to PBS, xp< 0.05 to NS. (b) MS
MDSCs improved fractional area change over NS cells or
PBS. *p < 0.05 to PBS, xp < 0.05 NS cells.
Table 1. Fractional Shortening and Fractional Area Data from Echocardiographic Analyses
of Function in Hearts at 2, 6, and 12 Weeks After Myocardial Infarction and Cell Injection
2 weeks 6 weeks 12 weeks
MS
FS 28%– 1%, n = 13, p= 0.01 to NS,
p = 0.01 to PBS
24%– 1%, n= 13, p = 0.01 to NS,
p= 0.01 to PBS
24%– 1%, n= 8, p = 0.049 to NS,
p= 0.01 to PBS
FAC 27%– 1%, n = 13, p= 0.01 to NS,
p = 0.01 to PBS
28%– 1%, n= 13, p = 0.049 to NS,
p= 0.01 to PBS
27%– 1%, n= 13, p = 0.16 to NS,
p= 0.01 to PBS
NS
FS 19%– 1%, n = 13, p= 0.16 to PBS 19%– 1%, n= 13, p = 0.02 to PBS 18%– 1%, n= 11, p = 0.38 to PBS
FAC 21%– 1%, n = 13, p= 0.03 to PBS 24%– 1%, n= 13, p = 0.01 to PBS 24%– 1%, n= 11, p = 0.11 to PBS
PBS
FS 16% – 2%, n = 8 15%– 1%, n = 14 15%– 1%, n = 5
FAC 15% – 1%, n = 8 15%– 2%, n = 14 18%– 1%, n = 5
Data are the mean– SEM.
PBS, phosphate-buffered saline; NS, nonstimulated; MS, mechanically stimulated; FS, fractional shortening; FAC, fractional area change.
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tissues containing progenitor cells are under constant me-
chanical stress, few studies have directly investigated the
influence of these mechanical forces on stem cells and their
regenerative potential. We hypothesized that the transplan-
tation of MDSCs exposed to mechanical loading prior to
transplantation would result in increased repair of the
myocardium after myocardial infarction. Studying the effects
of mechanical stimulation on cardiac muscle was based on a
number of previous studies showing mechanically governed
responses in cells and cellular components.38–40 On a mo-
lecular level a study on actin-network growth in vitro
showed that the velocity of growth was a function of the
previous loading applied to the network.39 Although this
study was on isolated actin filaments, it showed that the
loading history of cells may also play an important role in
determining future cellular behavior. Application of me-
chanical stretch to cultured adult rat muscle satellite cells
resulted in the release of hepatocyte growth factor and ac-
celerated entry into the cell cycle.40 In addition, in a coculture
system with rat neonatal cardiomyocytes, skeletal muscle
stem cells can differentiate into cardiomyocytes when me-
chanical loading is applied.38
We first examined whether using MDSCs exposed to
mechanical stimulation in vitro prior to transplantation could
improve regeneration in vivo. We found that the transplan-
tation of MS cells into a mouse model of myocardial infarc-
tion resulted in significant preservation of cardiac function
compared to NS cells and PBS alone. As MDSCs do not
appear to contribute directly to cardiomyocyte regeneration
through their differentiation into a cardiomyocyte lineage or
fusion with existing cardiomyocytes, the likely mechanism
for MS-MDSC cardiac recovery is improved angiogenesis, as
this has been previously shown to be critical for cardiac re-
pair after injury and disease.18,41
To support our in vivo results, we explored MDSC be-
havior in vitro under a variety of conditions. We observed an
increased secretion of VEGF after mechanical stimulation,
which may partially explain the improvement in MS MDSC
engraftment and repair and further supports our earlier re-
sults.18 Previous reports suggest that VEGF influences
myoblast migration and survival and increases skeletal
muscle repair during ischemia.42,43 Kasper et al. showed that
the conditioned medium from mesenchymal stem cells sub-
jected to mechanical loading increased sprouting of endo-
thelial cells by creating an angiogenic promoting
environment.44 Certainly other paracrine factors besides
VEGF could also be playing a role in the improvement of
cardiac function imparted by the MS MDSCs. For example,
the conditioned medium of MS mesenchymal stem cells had
an upregulation of MMP-2 and TGF-B1,44 which is an area
for future study.
As cells and the body are controlled by tightly regulated
spatiotemporal processes, it has been shown by numerous
groups that it is not just the addition or removal of stimu-
lation,45,46 but rather the controlled timing of the stimuli
that produces distinct results.47 Results from our VEGF
secretion study also demonstrate that the effect of MS is
time dependent. Interestingly, the increased secretion of
VEGF, while being significant at 24 h, required continued
mechanical stimulation and was reversible as the growth
factor levels returned to close to baseline levels within 24 h
after cessation of stretch. Just as spatiotemporal control of
FIG. 4. Mechanical preconditioning increases neoangiogenesis. (a) MS-MDSCs have increased angiogenesis above NS cells
and PBS, while NS had higher angiogenesis than PBS in the peri-infarct region at 12 weeks (*p < 0.05 to PBS, #p < 0.05 to NS
cells). (b) In the engraftment area, there is a slight increase in angiogenesis in the MS cell group above NS at both 6 and 12
weeks ( p = 0.34 for 6 weeks, p = 0.18 for 12 weeks).
FIG. 5. Mechanical stimulation of MDSCs prior to im-
plantation reduced scar tissue formation. (a) Although no
significant difference was observed between the MS and NS-
MDSC, PBS-injected hearts had significantly higher levels of
scar tissue than the MS group (*p< 0.05 to PBS). (b–d) Re-
presentative images of hearts injected with PBS, NS, and MS
MDSCs, respectively. Color images available online at www
.liebertonline.com/tea
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chemical factors is critical in regeneration, the time course
and duration of the mechanical stimulation could be just as
important. The tight regulation and timing demonstrated
by these results suggest that the mechanical loading history
can predispose the MDSCs toward specific responses that
are advantageous for cell transplantation. This is an essen-
tial point in this study since it shows that adding mechan-
ical stimulation before transplantation into a mechanical
environment is both a valid means of increasing VEGF se-
cretion and improves transplantation results. We speculate
that after intracardiac implantation, the MS-MDSCs un-
dergo a mechanical stretching regiment dictated by the host
microenvironment that complement the mechanical stimu-
lation in vitro and lead to a constant expression of VEGF.
Further study is necessary to fully optimize the mechanical
preconditioning regimen.
Another noteworthy finding of our current study is that
mechanical preconditioning of MDSCs before transplanta-
tion ameliorated the negative remodeling and scar tissue
formation of the injected hearts when compared with the PBS
group; however, the effect on scar tissue formation was only
significant in the MS-MDSC group. These results, taken to-
gether, suggest that the paracrine effect imparted by the in-
jected MDSCs plays a major determinant in cardiac repair
after stem cell implantation. It is important to note that these
studies were carried out in immunodeficient mice and that
the lack of immune system may influence the paracrine-
mediated healing response. This current study further dem-
onstrates that cardiac differentiation of the injected MDSCs is
not a prerequisite for improving cardiac function in infarcted
myocardium.
In summary, our results suggest that MS-MDSC trans-
plantation significantly improved cardiac contractility, sig-
nificantly increased the numbers of CD31 + cells in the
peri-infarct area, and significantly decreased fibrosis com-
pared with the PBS injected hearts in the injured myocar-
dium in a more effective manner than NS-MDSCs. These
findings highlight an important role for cyclic mechanical
loading preconditioning to improve the regeneration capac-
ity of MDSCs within the injured myocardium.
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